Synapse - Howard Scher

Results (1133)

Androgen deprivation therapy for biochemical recurrence in patients with seminal vesicle invasion after radical prostatectomy

Meeting Abstract

Secin, F. P.; Bianco, F. J.; Vickers, A. J.; Sogani, P.; Scher, H. I.; Scardino, P. T.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

The revised Memorial Anxiety Scale for Prostate Cancer (MAX-PC-R): Validation of a scale to measure anxiety in men with prostate cancer

Meeting Abstract

Roth, A. J.; Nelson, C. J.; Rosenfeld, B.; Warshowsky, A.; O'Shea, N.; Scher, H. I.; Breitbart, W.; Holland, J. C.; Curley-Smart, T.; Reynolds, T.
Psycho-Oncology (2005)

Fulltext@MSK | Save

Reverse transcriptase polymerase chain reaction for prostate-specific antigen (RT-PCR PSA) responses may predict time to progression (TTP) in hormone refractory prostate cancer (HRPC) patients treated with chemotherapy

Meeting Abstract

Ross, R. W.; Manola, J.; Hennessy, K.; Galsky, M.; Scher, H.; Small, E.; Kelly, W. K.; Kantoff, P.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Phase II study of boriezomib for castrate metastatic prostate cancer (PC)

Meeting Abstract

Morris, M. J.; Beekman, K. W.; Kelly, W. K.; Slovin, S. F.; Shaffer, D.; Eicher, C.; Chu, E.; Curley, T.; Delacruz, A.; Scher, H. I.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)

Meeting Abstract

Milowsky, M. I.; Galsky, M.; Lewin, J.; Rozario, C. P.; Owens, L.; Marshall, T.; Nanus, D.; Webb, I. J.; Scher, H. I.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Association of age, baseline characteristics, co-marbidity and toxicity in castrate metastatic prostate cancer patients (CMPC) treated with chemotherapy

Meeting Abstract

Fleming, M. T.; Beekman, K. W.; Warren, M.; Wilton, A.; Heller, G.; Scher, H.; Kelly, W. K.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors

Meeting Abstract

Eiseman, J. L.; Guo, J.; Weinbaum, B.; Ramanathan, R. K.; Belani, C. P.; Solit, D. B.; Scher, H. I.; Ivy, S. P.; Zuhowski, E. G.; Egorin, M. J.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer

Meeting Abstract

Daigneault, L.; Panchal, C.; Scher, H. I.; Slovin, S. F.; Rabbani, S.; Dulude, H.; Garde, S.; Ruiz, M.; Wu, J.; Hawkins, R.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Prognosis after androgen deprivation therapy in men with a rising PSA after prostatectomy

Meeting Abstract

Bianco, F. J.; Kattan, M. W.; Beekman, K. W.; Scher, H. I.; Scardino, P. T.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Outcomes with second-line chemotherapy in castrate metastatic prostate cancer

Meeting Abstract

Beekman, K. W.; Fleming, M. T.; Scher, H. I.; Warren, M.; Ishill, N.; Heller, G.; Kelly, W. K.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save